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Objectives: In Africa, single-dose nevirapine (NVPsd), short regimens of zidovudine (ZDV) or 
ZDV+lamivudine (3TC) are recommended to prevent peripartum mother-to-child HIV 
transmission (PMTCT). We evaluated the six-week field efficacy of two more PMTCT drug 
combinations. Design: An open-label intervention cohort in Abidjan. Methods: In 2001-2002, 
consenting women started oral ZDV 300mg bid at ≥36 weeks of gestation, with 600mg of ZDV 
+ 200mg NVPsd orally at beginning of labour. In 2002-2003, the antepartum regimen at 
≥32weeks comprised ZDV as previously + 3TC 150mg bid; the labour dose comprised 
ZDV+NVPsd as previously + 300mg 3TC orally. Neonates received ZDV syrup (2 mg/kg/6 
hours) for 7 days + NVPsd syrup (2mg/kg) on Day 2 in both periods. Each woman was assisted 
to either use breast milk substitutes or breastfeed exclusively. Pædiatric HIV infection was 
diagnosed by plasma HIV RNA viral load at 4 weeks, confirmed at 6 weeks. The reference 
group was a cohort receiving a short regimen of ZDV ≥36-38 weeks in 1995-2000 in the same 
population. Results: 1144 HIV-infected pregnant women were included: 351 with ZDV, 420 
with ZDV+NVPsd and 373 with ZDV+3TC+NVPsd; 1010 livebirths were eligible for analysis; 
79 children were HIV-infected peripartum. Six-week transmission probability was 6.5% (95% 
confidence interval 3.9-9.1%) with ZDV+NVPsd, a 72% reduction compared to ZDV alone (52-
88%; p=0.0002 adjusted on maternal CD4, clinical stage and breastfeeding). It was 4.7% (2.4-
7.0%) with ZDV+3TC+NVPsd (p=0.34 compared to ZDV+NVPsd). Conclusions: A short-
course of ZDV+NVPsd prevents most peripartum HIV transmission in Africa. This regimen 
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INTRODUCTION 
Mother-to-child transmission (MTCT) of HIV type 1 accounts for most of the 2000 newly 
acquired pædiatric HIV infections in Africa each day (1). Several antiretroviral (ARV) 
regimens to prevent MTCT have been successfully evaluated and are recommended by the 
World Health Organization (WHO) since 2000 (2). Two ARV drugs are thus used in 
monotherapy: zidovudine (ZDV) and nevirapine (NVP). 
ZDV given for the last four weeks of pregnancy plus the labour/delivery period has been 
evaluated in two placebo-controlled randomized trials in West Africa (3, 4). Transmission risk 
was 14.7% at six weeks compared to 24.8% with placebo, despite predominant breastfeeding 
exposure allowing for early HIV postnatal transmission (5). Open-label cohort studies 
confirmed the field efficacy or effectiveness of this ZDV regimen (6). The efficacy of 
maternal and neonatal NVP single dose (NVPsd) prophylaxis has been demonstrated first in a 
randomized controlled trial in Uganda with a six-week transmission rate of 11.8% (7). 
Another trial in South Africa demonstrated the statistical equivalence at six weeks of a NVP 
regimen, adding a second postpartum maternal NVP dose to the previous regimen, compared 
to a dual regimen of ZDV+lamivudine (3TC), 12% versus 9% (8). 
Combinations of ARVs may further reduce MTCT in Africa as in Europe and in the USA (9). 
Although succesufully evaluated in South Africa (8), in a multi-country African trial (10) and 
in France (11), the ZDV+3TC combination may induce neonatal anemia and viral resistance 
after ≥2 months of use and thus remains infrequently used. 
We conducted a cohort study in Abidjan, Côte d'Ivoire to evaluate the acceptability, tolerance 
and effectiveness of: 1) a short-course peripartum ZDV regimen combined with NVPsd 
during labour (ZDV+NVPsd) and followed by a very short neonatal prophylaxis of 




 Study setting 
 The ANRS 1201/1202 DITRAME PLUS project was conducted in two districts of 
Abidjan. HIV counselling and testing services were set up within the antenatal clinics of the 
Yopougon University Hospital and six community-run health facilities. Two sites served for 
enrolment and follow-up. 
 Study design 
 The study was an open-label intervention cohort. The study protocol was approved by 
the National Ethical Committee in Côte d’Ivoire and the French Agence Nationale de 
Recherches sur le SIDA (ANRS). The pooled data of two consecutive series of mother-infant 
pairs, receiving  ZDVin the ANRS 049a trial in 1995-1998 (4) or in a cohort on the same sites 
in 1999-2000 (6), were used for comparison. This regimen consisted of 300mg ZDV tablets 
twice a day at ≥36 weeks of gestation, two tablets (600mg) at beginning of labour and one 
week of maternal ZDV  postnatally but no neonatal prophylaxis. 
 Inclusion procedures 
 All pregnant women attending the selected clinics were offered pre-test counselling 
and HIV testing. Those ≥18 years old, at <32 weeks of gestation, living within the city limits 
and signing an informed consent were eligible. All serum samples were screened on site for 
HIV antibodies by an immunochromatographic rapid test (Determine ®, Abbott Laboratories, 
Abbot Park, IL, USA). A negative diagnosis was based on this single test result. Positive 
samples were immediately confirmed on site by a second rapid test (Genie II ®, Bio-Rad, 
Marnes-La-Coquette, France). Announcement of the seropositive status was made if both test 
results were positive. Women who tested positive with the two rapids tests or whose test 
results needed confirmation in the CeDReS reference laboratory (12) were systematically 
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offered to enter the cohort if hæmoglobinæmia was ≥7 g/deciliter (dl). Eligible women were 
scheduled for enrolment no later than at beginning of labour. 
 Study medications 
 The drug combination regimen evaluated in 2001-2002 consisted of a daily antenatal 
oral regimen of 300mg ZDV tablets twice a day at ≥36 weeks, two tablets (600mg) of ZDV 
and a single NVP tablet (200 mg) at beginning of labour. The intrapartum package was given 
at inclusion. Intra-partum treatment was self-initiated by the woman as soon as the labour had 
started. A second intra-partum dose was given by the study team if women did not deliver 
within 48 hours of administration of the first labour dose. In 2002-2003, the antenatal regimen 
was changed to ZDV 300mg and 3TC 150mg tablets twice a day at ≥32 weeks, followed by 
two tablets of ZDV (600mg) and 3TC (300mg) at beginning of labour plus NVPsd as 
previously. The ZDV+3TC maternal regimen was continued for three days post-partum. The 
neonatal prophylaxis was the same in the two periods. At delivery the mother was given a 
container with ZDV syrup for her neonate with a mono-dose syringe, four times a day (2 
mg/kg) for seven days. Mothers were also asked to attend the study clinic 48-72 hours after 
birth for directly observed administration of 2 mg/kg of NVPsd syrup to their neonate.  
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 Women were advised at inclusion and during subsequent prenatal visits to either 
choose artificial feeding from birth (13) or exclusive breastfeeding with initiation of weaning 
as soon as possible ≥4 months of life (14). Women were given support once their choice 
made, including free provision of equipment and supplies up to nine months postpartum (15). 
 Follow-up procedures 
 Demographic, clinical information, maternal CD4 measured by flow cytometry and 
HIV-1 RNA plasma viral load were processed at entry in the study. Women were given 
weekly then bi-weekly prepartum appointments for interview, clinical follow-up, drug 
distribution, verification of drug intake and tolerance. An appointment was given ≤48 hours 
after delivery, then a week later at the end of the treatment period, and at weeks 4 and 6 
postpartum. The clinical follow-up of the child followed the same schedule. Children’s blood 
samples were obtained for diagnosis of HIV infection and hæmoglobin measurement. Medical 
and psycho-social support was provided between scheduled visits. All prescribed medications, 
hospital stays and transportation were provided free of charge. 
 Study outcomes 
Diagnosis of pædiatric HIV infection 
 Capillary blood was collected in EDTA microtainer tubes in new-borns at day 2; 1-2 
ml of peripheral blood was taken at weeks 4 and 6. All samples collected at week 4 were 
processed for plasma RNA viral load measurement. The bDNA Versant HIV RNA kit version 
3.0 (Bayer Diagnostics, Emeryville, CA, USA) was applied to the ZDV cohort. A real time 
PCR (quantitative Taqman technology) was applied to cohorts with combination drug 
regimens. Compared to the bDNA assay, the real time PCR has shown 100% sensitivity and 
specificity  (95% lower bounds of 93.7% and 98.3%, respectively) (16, 18). The same 
techniques were applied to the preceding available sample(s) and to the six-week sample if 
the first one tested was positive. Both assays were controlled by the ANRS quality assurance 
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programme. The diagnosis of pædiatric HIV-1 infection was made on the basis of two 
positive virology tests (17). All samples with plasma HIV RNA >5000 copies/ml were 
considered positive (16, 18). The first positive test in the series allowed the estimation of the 
timing of infection: in utero if the day 1-4 specimen was positive, intrapartum / early 
postpartum if the day 1-4 specimen was negative but the week 4-6 specimen positive and 
timing of peripartum infection remained unknown in other instances (17). Absence of 
infection was defined by a negative test at the last time point an assay was done. Those 
children who had no sample available for testing and could not be followed >6 weeks were 
considered of definitive unknown HIV status. 
Adverse events 
 Neonatal severe anæmia was defined by hæmoglobinæmia <8 g/dl at week 4. All 
stillbirths, early neonatal (≤7 days) and neonatal (<28 days) deaths were taken into account. 
The frequency of maternal and neonatal clinical rash was estimated seven days after 
delivery/birth. 
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 Statistical analysis 
The sample size of the ZDV+NVPsd cohort was calculated to estimate a 6-week 
MTCT risk  of 7.5%, twice lower than with ZDV alone in a predominantly breast-feeding 
population (5), with a 5% type-I error (two-sided), a 10% type-II error and 10% of 
ininterpretable observations. This part of the study was terminated when its Scientific 
Committee after reviewing the available data concluded to the superiority of the ZDV+NVPsd 
combination compared to ZDV alone. The next regimen, ZDV+3TC+NVPsd, was then 
evaluated. This part of the study was terminated when highly active antitretroviral 
combination therapy (HAART) became available on site for the prevention of MTCT. To 
guarantee statistical independence of observations, we selected the first livebirth when a 
woman gave multiple livebirths (17). Group comparisons used variance analysis, Student's t-
test or non parametric Mann-Whitney test for quantitative variables, Chi-2 test or Fisher’s 
exact test for qualitative variables. The 6-week probability of infection was estimated using 
the Kaplan-Meier survival technique considering age at infection as the mid-point between 
the last negative and the first positive test results (17). All factors potentially associated with 
MTCT were studied in univariate then bivariate analyses adjusted on treatment. Cox 
multivariate proportional hazards model was used to study the relative effectiveness of each 
treatment, expressed as one minus the hazard ratio (HR). Multivariate analyses of the effect of 
treatment used as adjustment variables those with p<0.25 in bivariate analyses or p<0.05 in 
the comparison of the treatment groups. The role of interaction terms was investigated. Point 




 Between September 1995 and July 2003, 1144 pregnant women were enrolled: 351 
received ZDV alone, 420 ZDV+NVPsd and 373 ZDV+3TC+NVPsd. There were 1120 
maternal records available for analysis, of whom 56 women were lost to follow-up prior to 
delivery (Table 1). After exclusion of the multiple birth outcomes, the total number of births 
selected was 1064, including 22 stillbirths. Thirty-two eligible livebirths could not be taken 
into account in the analysis, without any blood sample available (n=17) and death in the first 
week of life (n=15). The baseline and follow-up characteristics of the cohorts are summarized 
in Table 2. The proportion of women eligible for HAART according to the 2003 WHO 
criteria (clinical stage 4 or clinical stage 3 and CD4<350/mm3 or stage 1-2 and 
CD4<200/mm3) (19) was 20.8%, including all the women (14.5%) with CD4<200. 
Treatment intake 
The median length of antenatal treatment was 21 days with ZDV, 29 with 
ZDV+NVPsd and 50 with ZDV+3TC+NVPsd (Table 2). The proportion of women taking the 
ARV labour dose increased from 83% with ZDV alone to 93% with the two drug 
combinations (p<10-4). The postpartum ARV prophylaxis was generally taken. This 
component could not be compared between the groups as it differed (Table 2). There was no 
statistical difference between the three groups for place of delivery and frequency of cesærian 
section, an infrequent practice (Table 2). The proportion of women who chose to breastfeed 
from birth was 54-66% in the two groups receiving ARV combinations, whereas it was 97.6% 
in the ZDV group (Table 2). 
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Tolerance 
Maternal tolerance to the three drug regimens was good (Table 3), with a 0.5% 
incidence of severe anemia in the first month postpartum. One woman, 32 years old, WHO 
clinical stage 1, 228 CD4/mm3 and 8.1 g/dL of hæmoglobinemia, initiated ZDV+3TC at 32 
weeks of gestation but stopped prophylaxis after four weeks with an hæmoglobinemia of 3.5 
g/dL, corrected by a blood transfusion. Her child was infected in utero. There was no report of 
grade III or IV rash after the maternal NVPsd intake during labour. Severe neonatal anemia 
was observed in 20 instances (2.2%), always transient. There was no report of grade III or IV 
rash after the neonatal NVPsd intake. The frequencies of perinatal deaths (stillbirths and early 
neonatal deaths) and low birthweight were comparable (p=0.17 and 0.28, respectively, tables 
1 and 3). All neonatal deaths but two were recorded in the first week of life and their 
frequency was comparable between the three groups (p=0.74, table 3). All but one remained 
of indeterminate HIV status, without any relation with infant feeding modality. 
Effectiveness 
There were 79/1010 neonates for whom the diagnosis of pædiatric HIV infection was 
made (Table 1). For 29 of them, in utero transmission was considered. In 28 instances, 
transmission was classified as intrapartum or early postnatal, the 22 other infections 
remaining of unknown timing. The overall six-week probability of transmission was 6.5% (CI 
3.9-9.1%) with ZDV+NVPsd and 4.7% (CI 2.4-7.0%) with ZDV+3TC+NVPsd (p=0.34 after 
adjustment on maternal CD4 count, plasma HIV-1 RNA, WHO clinical stage, primigravida, 
duration of prepartum treatment, intrapartum treatment intake, low birthweight and 
breastfeeding). When using ZDV alone as reference (12.5% transmission at six weeks), the 
protective effect of the two drug combinations was strong, with an adjusted effectiveness of 
72% (45-86%) for ZDV+NVPsd and 76% (52-88%) for ZDV+3TC+NVPsd (p<0.0002 and 
0.0001, respectively after adjustment for maternal CD4 count, WHO clinical stage, moderate 
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anemia, age, primigravida, low birthweight, duration of prepartum treatment, intrapartum 
treatment intake, cesæerian section and breastfeeding) (Table 4). There was neither an 
interaction between treatment and maternal CD4 count (p=0.68) nor between treatment and 
infant feeding (p=0.57). There was no statistical difference in the crude and adjusted risks of 
transmission at six weeks according to the infant feeding exposure. This adjustment factor 
never reached statistical significance in multivariate analyses (p=0.10, Table 4). Thus, 
compared to ZDV alone, the relative effectiveness of the two drug combinations among the 
703 breastfed children was 70% for ZDV+NVPsd (p<0.002) and 77% for ZDV+3TC+NVPsd 
(p<0.003). 
We stratified the sample according to the 2003 WHO criteria for HAART indication 
(p=0.65 for the interaction of this variable with treatment). Among the 212 HAART eligible 
women, the six-week probability of peripartum infection was 23.6% with ZDV alone, 13.6% 
with ZDV+NVPsd and 9.1% with ZDV+3TC+NVPsd (p=0.28 and 0.10, respectively for the 
two comparisons using ZDV as reference). Among the 774 women who had no HAART 
indication, the six week peripartum transmission probability was 10.9% with ZDV alone, 
3.6% with ZDV+NVPsd and 3.5% with ZDV+3TC+NVPsd (p<0.03 for both comparisons 
using ZDV as reference).  
We could not investigate the relationship between the ARV regimens and the timing 
of acquisition of pædiatric HIV infection as the majority of cases in the ZDV cohort were 
HIV RNA positive for the first time at ≥Day 7 (Table 1). Finally, the time period of enrolment 
was not investigated as the study of each drug regimen followed the previous one without any 
overlap. We verified however that the transmission rate did not vary by calendar year for each 




We conclude to the high effectiveness of ZDV+NVPsd, reducing by 72% peripartum 
MTCT compared to ZDV alone (3-6). We cannot demonstrate an additional benefit of adding 
3TC to ZDV+NVPsd although starting ZDV+3TC a month earlier than ZDV. It is now 
internationally recognized that triple drug combinations used together and not sequentially 
further reduce MTCT, especially for women who need HAART for themselves (20). 
However, we identified with ZDV+NVPsd a peripartum regimen that is particularly effective 
when HAART is not indicated, with comparable results to industrialized countries before the 
HAART era (9, 21). The six-week residual risk was independant of the breastfeeding 
exposure. The prolonged duration of NVP levels in both the mother and the child over the 
first weeks of life may have reduced early transmission by breastmilk, an added benefit of 
NVPsd combined with ZDV or ZDV+3TC. Two-year follow-up is under way to estimate the 
additional postnatal transmission risk and the cumulative effectiveness of our peripartum and 
postpartum packages (15). 
Comparing directly the different ARV MTCT regimens is difficult. The first African 
placebo-controlled trials evaluated individual drug regimens (3, 4, 7, 10). Then, equivalence 
trials were designed (8). Three key parameters have varied from trial to trial and impair the 
direct comparison of published results. The median maternal CD4 count varied between 
545/mmm3 in West Africa ZDV studies (5) to 370 with ZDV+NVPsd (Table 2), 461 in the 
Uganda NVPsd trial (7) and 482 in the ZDV+3TC trial (10). The frequency of cesærian 
section was 30% in South Africa (8), 3-6% in our cohort and exceptionnally elective. We 
introduced alternatives to prolonged and predominant breastfeeding whereas no neonatal 
intervention had been proposed in the ZDV reference cohort. Our estimate of the six-week 
transmission risk includes early postnatal transmission, possibly partly controlled by the 
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neonatal ZDV+NVPsd prophylaxis but impaired by other risk factors, low maternal CD4 and 
low frequency of cesærian section. These three factors were controlled for in all analyses. In 
doing so, our ZDV+NVPsd regimen had the lowest estimate of the residual transmission risk 
compared to ZDV alone (3, 4), NVPsd (7), ZDV+3TC, except its longest regimen with a 
residual transmission of 5.7% (10). 
The DITRAME PLUS regimens were made of several components, each of them selected 
based on previous evidence. We did not design the study to investigate their respective 
contribution as recently done in Thailand in a randomized trial (22). Indeed, their results 
strengthen our approach of  adding NVPsd to a short-course ZDV regimen. This trial suggests 
also that the neonatal ZDV+NVPsd prophylaxis has an added value, with a 2.0% residual 
transmission versus 2.8% in the absence of neonatal NVPsd, although the difference remained 
below statistical significance (22). Neonatal NVPsd together with one week of ZDV has 
recently been shown to prevent more intrapartum transmission than NVPsd in Malawi when 
no ARV could be given before delivery/birth (23). This was not the case however when 
maternal NVPsd had been administered prior to delivery (24). Based on these evidences, 
WHO recommends as first line regimen the combination of a short-course of ZDV for 
pregnant women at ≥28 weeks and children, for at least one week, with NVPsd for both (20). 
We chose a nonrandomized approach to estimate the treatment effect as we considered 
there was a priori lack of equipoise between ZDV+NVPsd and ZDV alone. Indeed, ethical 
principles and time constraints can legitimize the use of nonrandomized designs (25). The 
Thai trial conducted at the same time than our study stopped its ZDV alone arm after its first 
interim analysis as it was already inferior to the two arms evaluating ZDV+NVPsd 
combinations (22). We acknowledge that beyond important confounding factors 
systematically controlled for, e.g. the clinical and immunological stage of HIV disease, the 
breastfeeding exposure and the duration of the ARV prophylaxis, unconsidered factors could 
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not be taken into account by our design. Of note, the uptake in the cohorts remained constant 
over time (26).  
Viral resistance has not been a concern with short-course ZDV (27). In the Uganda 
NVPsd trial, the resistance mutations were transiently diagnosed in 19% of the mothers but 
were not associated with transmission (28, 29). The acquisition of different patterns of 
transient resistance by 46% of the infected children in this trial was considered due to the 
neonatal NVPsd rather than to the transmission of resistant virus (29). Using NVPsd in 
combination with other drugs, the incidence of viral mutations at six-week postpartum was 
15% in industrialized countries (30). Early results of resistance studies within our cohort 
confirm that NVP resistance occurs at a high frequency among mothers (33%) and children 
(23%) despite the use of ZDV+NVPsd instead of NVPsd (31). Further studies will determine 
whether resistance to 3TC has been added to resistance to NVPsd (11, 32) and conversely, if 
the three-day maternal postpartum ZDV+3TC regimen has influenced or not the occurrence of 
maternal NVP resistance (33). The consequences of viral resistance after NVPsd exposure on 
the subsequent response to HAART in women and children should be urgently investigated in 
Africa like in the Thai trial (34) considering the possible large-scale adverse effect on 
subsequent treatment options. 
The ZDV+3TC+NVPsd regimen we evaluated was selected at a time access to HAART 
was too limited in Côte d’Ivoire to be considered during pregnancy. Our choice was based on 
the demonstrated efficacy of short-courses of ZDV+3TC in the ANRS 075 cohort in France 
(11) and in the PETRA trial in Africa (10). We did not demonstrate an enhanced effectiveness 
of this regimen compared to ZDV+NVPsd, although our study had limited statistical power, 
an uneven distribution of confounding variables between the two groups (controlled for in the 
analysis) and was terminated mid-2003 as soon as HAART became available on site. 
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The ZDV+NVPsd MTCT prophylactic regimen we evaluated is now part of the list of 
internationally recommended drug regimens by WHO (20). Once the benefit (effectiveness) / 
risk (resistance) ratio of the ZDV+3TC+NVPsd combination is known, this regimen may also 
be considered. Four areas now require further research consideration. First, the uptake of 
ARV peripartum interventions is critical to obtain a public health impact. ZDV and NVPsd 
are not easy to use in Africa (35-37). Their combined use will not be necessarily more 
complex but the challenge is to improve coverage (26). Second, the reduction of the risk of 
postnatal transmission should be adressed, either with infant feeding strategies (15) or with 
ARV-based approaches (38). Third, alternatives to NVPsd containing regimens should be 
investigated as viral resistance and impaired response to subsequent ARV treatment is a 
serious concern. Finally, the residual transmission we observed with ZDV+NVPsd cannot be 
considered fully satisfactory. HAART is now universally recommended for pregnant women 
who fulfill this indication for themselves (20). We demonstrate in a large African cohort, like 
in a randomized trial in Thailand, that a short-course peripartum ZDV  regimen combined 
with NVPsd is more effective than previously used single drug regimens and will greatly 
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Table 1. Number of women and children by treatment group in the ANRS 1201/1202 








Women enrolled 373 420 351 
    Excluded 







Women analysed 372 (100%) 402 (100%) 346 (100%) 
    Lost to follow-up before delivery 23 (6.2%) 22 (5.5%) 11 (3.2%) 
Women who gave birth 349 380 335 
    Multiple birth outcomes excluded  







Single or first births analysed 349 (100%) 380 (100%) 335 (100%) 
    Stillbirths 13 (3.7%) 5 (1.3%) 4 (1.2%) 
Livebirths analysed 336 (100%) 375 (100%) 331 (100%) 
    Not tested for paediatric diagnosis 







Included in the transmission analysis 329 (100%) 361 (100%) 320 (100%) 
Tested HIV positive ≤week 6 15 (4.6%) 23 (6.4%) 41 (12.8%) 
   Confirmed in utero infection (day 1 or 2) 7 10 3 
   Probable in utero infection (day 3 or 4) 3 4 2 
   Intra partum or early postnatal infection 3 8 17 
   Timing of peripartum infection unknown 2 1 19 
 
† second birth among twins; # second birth among 17 twin births, second and third 
births among two triplets 
3TC = lamivudine; NVPsd = single-dose nevirapine during labour; ZDV = zidovudine 
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Table 2. Baseline and follow-up characteristics of pregnant women and children: ANRS 1201/1202 DITRAME PLUS study 
 ZDV+3TC+NVPsd ZDV+NVPsd ZDV P1 P2 
Pregnant women enrolled 372 402 346   
    Median age in years (IQR) 27 (23-30) 26 (23-30) 25 (22-30) 0.03 0.31 
    Median parity (IQR) 1 (0-2) 1 (1-3) 1 (0-3) 0.07 0.07 
    Primigravida (%) 27 (7.3) 39 (9.7) 52 (15.2) 0.002 0.05 
    Median gestational age (IQR) at enrolment 33 (32-34) 36 (36-37) 36 (36-37) <0.0001 <0.0001 
    Median hæmoglobinemia in g/dL (IQR) 9.95 (9.2-10.8) 9.90 (9.0-10.7) 9.30 (8.5-10.3) <0.0001 0.37 
          % moderate anaemia (7-10g hæmoglobin / dL) 206 (55.4) 224 (55.7) 233 (68.3) <0.0001 0.90 
    Median lymphocyte CD4+ count/mm3 (IQR) 412 (265-580) 370 (243-552) 502.5 (327-714) 0.0003 0.03 
          <200 CD4+ cells /  mm3 (%) 53 (14.3) 75 (18.7) 34 (10.1) 0.004 0.10 
    WHO clinical stage 3-4 (%) 73 (19.6) 126 (31.3) 34 (10.1) <0.0001 0.0002 
     WHO clinical stage 4 / AIDS (%) 0 9 (2.2) 5 (1.5) 0.007 0.004 
    Indication for HAART  (2003 WHO criteria) * 75 (20.2) 117 (29.1) 43 (12.4) <0.0001 0.004 
     Median log10 HIV-1 RNA plasma viral load at enrolment (IQR) 4.45 (3.94-5.1) 4.40 (3.76-4.88) ** NA 0.003 
    Median  duration of prepartum treatment in days (IQR) 50 (34-63) 29 (18-40) 21 (13-32) <0.0001 <0.0001 
Women who delivered 349 380 335   
    Delivered at home (%)  39 (11.2) 35 (9.2) 41 (12.4) 0.36 0.38 
    With cesærian section (%) 21 (6.0) 19 (5.0) 10 (3.0) 0.16 0.55 
    Intrapartum treatment taken (%) 322 (92.5) 354 (93.2) 274 (83.3) <0.0001 0.75 
Women with livebirths analysed 336 375 331   
    Maternal postpartum (one week) ZDV (%) NA NA 308 (96.3)   
    Neonatal ZDV (one week) +NVPsd prophylaxis (%) 298 (88.7) 331 (88.3) NA NA 0.86 
    Children ever breastfed ≤4 weeks (%) 223 (66.1) 203 (54.1) 323 (97.6) <0.0001 0.0006 
p1  test for difference between the three groups ZDV, ZDV+NVPsd, ZDV+3TC+NVPsd 
p2 test for difference between the ZDV+NVPsd and ZDV+3TC+NVPsd groups; IQR interquartile range; NA not applicable 
3TC = lamivudine; NVPsd = single-dose nevirapine during labour; ZDV = zidovudine 
*HAART = highly active antiretroviral therapy if WHO clinical stage 4 or WHO clinical stage 3 and CD4<350 / mm3 or WHO clinical stage 1/2 and CD4<200 / mm3 
** 4.8 log10 for a sample of transmitting mothers and 3.7 for a sample of non transmitting mothers  
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Table 3. Maternal and neonatal biological tolerance to treatment, and neonatal mortality : ANRS 1201/1202 DITRAME PLUS study 
 
 ZDV+3TC+NVPsd ZDV+NVPsd ZDV p-value * 
Women who delivered 349 380 335  
Women with severe anæmia 









Severe rash <Day 7 postpartum 0 0 0 NA 
Children followed ≥1 day 336 375 331  
Children with severe anæmia (%) 








Severe rash <Day 7 0 0 0 NA 







Early neonatal deaths (≤7 days) 6 (1.8%) 6 (1.6%) 7 (2.1%) 0.86 
All neonatal deaths (<28 days) 8 (2.4%) 6 (1.6%) 7 (2.1%) 0.74  
3TC = lamivudine ; NVPsd = single-dose nevirapine during labour ; ZDV = zidovudine 
NA: not applicable 
a at day 28 postpartum for ZDV+3TC+NVPsd and ZDV+NVPsd ; at day 45 postpartum for ZDV 
*  test for difference between the three groups unadjusted for baseline differences 
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Table 4. Six-week probability of peripartum infection, bivariate and multivariate Cox proportional hazard model for the risk of mother-to-child transmission of HIV according to 
treatment group (reference: ZDV): ANRS 1201/1202 DITRAME PLUS study 





95% CI p§§ HR# 95% CI HR 95% CI p HR 95% CI p 
Treatment    0.002         
   ZDV 303 12.5 8.7-16.3  1 -  NA  1 -  
   ZDV+NVPsd 357 6.5 3.9-9.1  0.54 0.3-0.9    0.28 0.1-0.5 0.0002 
  ZDV+3TC+NVPsd 326 4.7 2.4-7.0  0.39 0.2-0.7    0.24 0.1-0.5 <0.0001 
Maternal CD4 count    0.0005     <0.0001   0.0026 
   [0-200[  147 15.6 10-22  3.61 1.9-6.9 4.47 2.3-8.6  3.83 1.9-7.7  
   [200-350[  232 9.1 6-13  2.00 1.0-3.9 2.45 1.3-4.8  2.31 1.1-4.6  
   [350-500[  244 7.5 4-11  1.64 0.8-3.2 1.91 0.9-3.8  1.94 0.96-3.9  
   > 500  363 4.6 2-7  1 - 1 -  1 -  
WHO clinical stage    0.002     0.0003   0.009 
   Stage 1-2 779 6.5 5-8  1 - 1 -  1 -  
   Stage 3-4 207 13.4 9-19  2.08 1.3-3.3 2.50 1.5-4.1  1.98 1.2-3.3  
Maternal moderate anemia    0.09     0.20   0.91 
   No 396 5.9 4-8  1 - 1 -  1   
   Yes 589 9.3 7-12  1.53 0.9-2.5 1.38 0.8-2.3  0.97 0.6-1.6  
Maternal age (for +10 years) - NA - 0.46 1.17 0.8-1.8 1.25 0.8-1.9 0.29 1.05 0.7-1.6 0.80 
Primigravida    0.59     0.4   0.44 
   No 889 8.1 6-10  1 - 1 -  1 -  
   Yes 97 6.5 2-12  0.80 0.3-1.8 0.69 0.3-1.6  0.71 0.3-1.7  
Prepartum treatment    0.13     0.32   0.43 
   < 7 days 47 16.2 5-27  1 - 1 -  1 -  
   [7-20] days 247 8.4 5-12  0.53 0.2-1.2 0.52 0.2-1.2  0.56 0.2-1.4  
   > 21 days 692 7.3 5-9  0.45 0.2-1.0 0.58 0.3-1.3  0.71 0.3-1.7  
Intrapartum treatment     0.18     0.41   0.67 
   No 91 11.5 5-18  1 - 1 -  1 -  
   Yes 895 7.6 6-10  0.64 0.3-1.2 0.75 0.4-1.5  0.85 0.4-1.8  
Cesærian section    0.16     0.22   0.23 
   No 939 8.3 7-10  1 - 1 -  1 -  
   Yes 47 2.1 0-6  0.27 0.04-2.0 0.29 0.0-2.1  0.30 0.04-2.2  
Low birthweight    0.0002     0.0003   0.0006 
   No 863 6.8 5-9  1 - 1 -  1 -  
   Yes 123 16.0 10-23  2.55 1.5-4.3 2.59 1.5-4.4  2.63 1.5-4.6  
Breastfed    0.96     0.12   0.10 
   Never 283 7.5 4-11  1 - 1 -  1 -  
   Ever 703 8.0 6-10  0.99 0.6-1.6 0.62 0.3-1.1  0.59 0.3-1.1  
* adjusted on treatment   ** variables with p<0.25 in bivariate analysis or p≤0.05 in the comparison of the three treatment groups (table 2) 
§ Kaplan Meier probability of infection at 6 weeks  §§ logrank test  # univariate analysis = unadjusted Cox proportional hazards model  
† 24 children / 1010 eligible for the transmission analysis (table 1)  are excluded for incomplete data 
CI confidence interval   HR hazard ratio   3TC = lamivudine; NVPsd = single-dose nevirapine during labour; ZDV =zidovudine 
Moderate anemia 7≤hæmoglobinemia≤10g/dL   Low birthweight <2500g 
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